

Press Release

Nicox: Half-year liquidity contract statement with Kepler Cheuvreux

January 11, 2021 - release at 7:30 am CET
Sophia Antipolis, France

Under the liquidity contract entered into between Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st, 2020:

- 147,145 shares
- € 394,966.53

- Number of executions on buy side on semester: 829
- Number of executions on sell side on semester: 609
- Traded volume on buy side on semester: 457,955 shares for € 1,916,480.01
- Traded volume on sell side on semester: 310,810 shares for € 1,312,111.94

As a reminder :

- the following resources appeared on the liquidity account when the activity started:
 - 0 shares
 - € 500,000.00

The liquidity agreement complies with AMF Decision n° 2018-01 dated 2nd July 2018, introducing liquidity agreements on equity securities as permitted market practice.

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	827	457,955	1,916,480.01	609	310,810	1,312,111.94
05/08/2020	3	1,000	3,840.00	-	-	-
06/08/2020	9	1,245	4,731.00	1	1	3.86
07/08/2020	5	2,000	7,540.00	-	-	-
11/08/2020	6	1,000	3,940.00	-	-	-
12/08/2020	2	1,300	5,252.00	3	800	3,240.00
13/08/2020	6	1,505	6,080.20	-	-	-
14/08/2020	5	1,495	5,994.95	-	-	-
17/08/2020	7	2,159	8,679.18	-	-	-
18/08/2020	2	73	292.00	-	-	-
19/08/2020	6	2,000	8,080.00	-	-	-
20/08/2020	8	1,789	7,093.69	1	1	4.03
24/08/2020	16	8,851	35,404.00	12	7,000	28,140.00
25/08/2020	16	5,149	20,441.53	11	2,000	7,960.00
26/08/2020	10	3,838	15,313.62	13	6,000	24,060.00
27/08/2020	16	4,163	16,527.11	7	2,703	10,757.94
28/08/2020	9	4,000	15,760.00	14	3,098	12,237.10
31/08/2020	4	3,000	11,760.00	5	1,402	5,565.94
01/09/2020	7	3,000	11,580.00	-	-	-
04/09/2020	7	6,000	23,100.00	-	-	-
08/09/2020	8	5,100	19,533.00	-	-	-
09/09/2020	3	1,400	5,292.00	1	-	-
10/09/2020	4	2,800	10,584.00	4	2,800	10,724.00
11/09/2020	26	12,492	46,345.32	-	-	-
14/09/2020	-	-	-	2	1,400	5,320.00
15/09/2020	-	-	-	6	4,200	16,170.00
16/09/2020	2	200	760.00	-	-	-
17/09/2020	15	5,400	20,628.00	1	13	50.18
18/09/2020	8	2,253	8,516.34	-	-	-
21/09/2020	14	5,896	21,992.08	1	1	3.80
22/09/2020	1	1,400	5,152.00	-	-	-
23/09/2020	2	2,800	10,220.00	6	1,400	5,194.00
24/09/2020	-	-	-	6	2,870	10,819.60
25/09/2020	1	660	2,376.00	-	-	-
28/09/2020	2	2,800	10,108.00	4	2,782	10,126.48
29/09/2020	-	-	-	3	2,818	10,229.34
30/09/2020	-	-	-	4	2,800	10,248.00
01/10/2020	1	500	1,825.00	2	411	1,516.59
02/10/2020	1	500	1,800.00	-	-	-
05/10/2020	7	1,400	4,970.00	-	-	-
07/10/2020	3	4,200	14,784.00	2	1,400	4,984.00
08/10/2020	6	1,400	4,900.00	1	999	3,526.47
09/10/2020	-	-	-	19	5,787	20,775.33
12/10/2020	-	-	-	8	4,414	16,111.10
13/10/2020	4	4,200	15,204.00	4	1,178	4,276.14
14/10/2020	6	4,200	15,078.00	2	7	25.41
15/10/2020	15	8,400	29,400.00	-	-	-
16/10/2020	2	1,400	4,872.00	3	3,038	10,724.14
19/10/2020	-	-	-	6	3,962	13,985.66
20/10/2020	-	-	-	1	1,400	5,040.00
21/10/2020	4	2,820	10,067.40	-	-	-
22/10/2020	5	2,780	9,813.40	1	1,400	4,970.00

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	827	457,955	1,916,480.01	609	310,810	1,312,111.94
23/10/2020	8	4,201	14,955.58	11	5,601	20,163.60
26/10/2020	9	2,800	9,912.00	5	2,855	10,308.55
27/10/2020	14	7,100	24,779.00	-	-	-
28/10/2020	24	11,600	38,978.00	-	-	-
29/10/2020	12	3,067	10,182.44	-	-	-
30/10/2020	9	2,900	9,802.00	12	4,227	14,329.53
02/11/2020	1	2,000	7,040.00	3	1,540	5,436.20
03/11/2020	-	-	-	28	8,835	32,336.10
04/11/2020	9	8,515	31,335.20	4	2,693	10,071.82
05/11/2020	8	6,872	25,701.28	9	3,563	13,396.88
06/11/2020	23	8,400	31,752.00	10	3,400	12,988.00
09/11/2020	6	2,903	11,205.58	19	6,300	24,507.00
10/11/2020	10	3,034	12,044.98	6	5,000	20,100.00
11/11/2020	6	5,334	21,175.98	1	315	1,266.30
12/11/2020	21	10,626	42,504.00	12	5,885	23,716.55
13/11/2020	3	442	1,812.20	23	8,818	36,065.62
16/11/2020	-	-	-	15	3,182	13,268.94
17/11/2020	4	2,800	11,816.00	1	1,400	5,964.00
18/11/2020	10	4,200	17,640.00	2	220	932.80
19/11/2020	24	14,001	58,244.16	-	-	-
20/11/2020	18	7,457	30,424.56	1	1,400	5,740.00
23/11/2020	2	279	1,166.22	23	15,180	63,604.20
24/11/2020	-	-	-	8	4,200	18,102.00
25/11/2020	1	675	3,010.50	13	9,800	43,806.00
26/11/2020	-	-	-	23	14,400	70,992.00
27/11/2020	7	5,600	32,424.00	15	8,400	50,064.00
30/11/2020	20	16,800	94,752.00	7	2,800	16,660.00
01/12/2020	41	24,000	125,520.00	11	8,311	44,879.40
02/12/2020	46	22,000	107,800.00	-	-	-
03/12/2020	17	15,000	70,350.00	-	-	-
04/12/2020	13	14,000	61,320.00	3	1,400	6,160.00
07/12/2020	1	1,400	6,216.00	9	2,800	12,824.00
08/12/2020	9	5,600	24,528.00	-	-	-
09/12/2020	8	4,200	18,144.00	6	4,720	20,768.00
10/12/2020	5	2,800	11,984.00	-	-	-
11/12/2020	14	9,800	41,944.00	11	9,280	40,924.80
14/12/2020	5	2,800	11,732.00	11	7,020	30,256.20
15/12/2020	25	15,000	63,750.00	16	7,580	32,897.20
16/12/2020	4	5,600	23,632.00	5	5,600	23,912.00
17/12/2020	3	4,200	17,808.00	2	1,400	6,020.00
18/12/2020	2	1,400	5,950.00	13	7,548	32,380.92
21/12/2020	23	18,244	76,259.92	6	4,594	19,386.68
22/12/2020	6	6,405	27,477.45	35	20,367	88,392.78
23/12/2020	14	11,152	47,172.96	11	8,400	35,784.00
24/12/2020	12	10,504	44,957.12	25	11,503	49,462.90
28/12/2020	20	8,075	34,480.25	15	4,056	17,521.92
29/12/2020	15	7,221	30,544.83	2	1,400	5,978.00
30/12/2020	1	1,400	6,104.00	26	16,732	73,955.44
31/12/2020	10	7,000	30,520.00	-	-	-

About Nicox

Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIAE™ in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

Analyst coverage

Bryan, Garnier & Co	Victor Floc'h	Paris, France
Cantor Fitzgerald	Louise Chen	New York, U.S.
H.C. Wainwright & Co	Yi Chen	New York, U.S.
Kepler Cheuvreux	Damien Choplain	Paris, France
Oppenheimer & Co	Hartaj Singh	New York, U.S.



The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Contacts

Nicox

Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com

Investors & Media

United States & Europe
LifeSci Advisors, LLC
Mary-Ann Chang
T +44 7483 284 853
mchang@lifesciadvisors.com

Media

France
LifeSci Advisors, LLC
Sophie Baumont
M +33 (0)6 27 74 74 49
sophie@lifesciadvisors.com

Forward-Looking Statements

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 3rd chapter of the '*Document d'enregistrement universel, rapport financier annuel et rapport de gestion 2019*' filed with the French *Autorité des Marchés Financiers* (AMF) on March 6, 2020 which is available on Nicox's website (www.nicox.com) and in the 4th chapter of the half yearly financial report as of June 30, 2020, which is also available on Nicox's website..

Nicox S.A.

Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99